Idenix Pharma (IDIX) Reports Better-Than Expected Q4 Loss of $0.25
More News related to IDIX
- Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
- Caris & Co Downgrades Idenix Pharmaceuticals (IDIX) to Above Average
- Morning Movers 10/30: PVFC, WPTE, CNXT, HPOL, TVL, MSTR Higher; NVTL, GFIG, TSRA, GGC, IDIX Lower
- Idenix (IDIX) Announces Presentations of IDx184 at AASLD in Boston
- Idenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis C Virus (HCV)
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) reports Q4 loss of $0.25, 5 cents better than the analyst estimate of ($0.30). Revenue for the quarter was $4.3 million, versus the consensus of $2.40 million.
Related Categories
EarningsStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
